Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group
about
A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancersMesenchymal Stem and Progenitor Cells in Normal and Dysplastic Hematopoiesis-Masters of Survival and Clonality?Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study GroupEarly B-cell factor 3 (EBF3) is a novel tumor suppressor gene with promoter hypermethylation in pediatric acute myeloid leukemia.A phase I and pharmacodynamic study of the histone deacetylase inhibitor belinostat plus azacitidine in advanced myeloid neoplasia.International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts.Selective Inhibitors of Histone Deacetylases 1 and 2 Synergize with Azacitidine in Acute Myeloid Leukemia.Low Dose Cytosine Arabinoside and Azacitidine Combination in Elderly Patients with Acute Myeloid Leukemia and Refractory Anemia with Excess Blasts (MDS-RAEB2)Digging deep into "dirty" drugs - modulation of the methylation machinery.Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classificationsClinical outcomes of AML patients treated with Azacitidine in Portugal: A retrospective multicenter studyThe Role of Azacitidine in the Treatment of Elderly Patients with Acute Myeloid Leukemia: Results of a Retrospective Multicenter Study.The double-edged sword of (re)expression of genes by hypomethylating agents: from viral mimicry to exploitation as priming agents for targeted immune checkpoint modulation.Treatment of elderly patients with acute myeloid leukemia with azacitidine results in fewer hospitalization days and infective complications but similar survival compared with intensive chemotherapy.Management of Newly Diagnosed Acute Myeloid Leukemia in the Elderly: Current Strategies and Future Directions.Therapeutic decision-making in elderly patients with acute myeloid leukemia: conventional intensive chemotherapy versus hypomethylating agent therapy.Response Rates as Predictors of Overall Survival: A Meta-Analysis of Acute Myeloid Leukemia Trials.Azacitidine Mitigates Graft-versus-Host Disease via Differential Effects on the Proliferation of T Effectors and Natural Regulatory T Cells In Vivo.Emerging strategies for the treatment of older patients with acute myeloid leukemia.Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study.Azacitidine: A Review in Myelodysplastic Syndromes and Acute Myeloid Leukaemia.DNA methylation aberrancies as a guide for surveillance and treatment of human cancers.Treatment of Low-Blast Count AML using Hypomethylating Agents.Real life experience with frontline azacitidine in a large series of older adults with acute myeloid leukemia stratified by MRC/LRF score: results from the expanded international E-ALMA series (E-ALMA+).Anakoinosis: Communicative Reprogramming of Tumor Systems - for Rescuing from Chemorefractory NeoplasiaLenalidomide, celecoxib, and azacitidine therapy for blastic plasmocytoid dendritic cell neoplasm: a case reportDecitabine improves progression-free survival in older high-risk MDS patients with multiple autosomal monosomies: results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study GroMolecular targeting in acute myeloid leukemiaNew drug approvals in acute myeloid leukemia: what's the best end point?A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with ⩽30% blasts.Azacitidine or intensive chemotherapy for older patients with secondary or therapy-related acute myeloid leukemia.Azacitidine in Lower-Risk Myelodysplastic Syndromes: A Meta-Analysis of Data from Prospective Studies.Time to response and survival in hypomethylating agent-treated acute myeloid leukemia.Pevonedistat, a first-in-class NEDD8-activating enzyme (NAE) inhibitor, combined with azacitidine, in patients with AML.Loss of response to azacitidine is associated with deletion 12p13 in a patient with myelodysplastic syndrome with unique translocation t(13;17)(q12;q25) after prior breast cancer and acute promyelocytic leukemia.Azacitidine as a bridge to allogeneic hematopoietic cell transplantation in a pediatric patient with Fanconi anemia and acute myeloid leukemia.
P2860
Q26743743-443C161A-EBC6-41AE-8361-CCF2C147F8FEQ26746104-B5B468E1-A57B-4C75-BF6F-050D675C2AD9Q31163049-1EB5ACC3-82E6-4339-95D3-C065E2D5D29AQ35030109-FE7EE0AB-458C-4E98-B714-8CC992D50148Q35327711-C095F565-1835-4969-AC3B-612CA016D5AEQ35859212-CAF803C9-9D6E-4DE0-8FFB-6585F15AA19BQ36242646-0B1D8AC0-A716-429A-B796-A47F6DC5EF40Q36522939-A973AD39-45A4-4D86-A255-7702A3A75D50Q36523796-7C939893-699C-4449-B42D-79529C02092CQ36804633-91F756A4-6F16-47DA-B778-31057E43E778Q37545335-D946BF2E-7E3E-4694-870C-D6502C732412Q37548245-4D3AD1A2-0E0B-48DF-A299-527E14A09428Q37731703-BF78533F-CE42-4F6A-9AEA-64893F9379D1Q38302235-3AD5F14C-D4DB-4352-9A45-CCEE8D329FA1Q38601723-792EC30A-81EF-4171-ACE1-6DC7ECF0B714Q38614756-A5229EF7-8E99-4A55-BA09-C0E854A44AAFQ38642017-CBA3B8A8-C9DD-4D39-A190-70ECF0F3F8E2Q38741352-CF640B5B-53B8-4C4F-A40E-B5A3B67457CDQ38818726-16C9BD6A-6D7F-406A-8D13-FA2CC17E7A5DQ38831810-634F576C-2280-402A-B33C-BBE31BB6B4A4Q38837834-5BA0386D-4DB8-4DB4-BA2E-71443F8EFD73Q39208639-644AA2F2-341F-4561-B100-DC27D2692DCBQ39429687-A0A3C230-12E6-4C23-9859-05347228FCD3Q40080790-63C7C25B-7D28-4C7A-A7F0-42057DE18627Q40640442-F4EAEA8A-77F8-4530-B678-C02C3688CC9AQ41067113-9005A79D-E060-4242-9CD7-1C74CD8662FFQ41104655-18119054-1528-4FF3-B86C-D894B6501DF8Q41558732-8EC6111A-A14C-43F4-A7D1-096F519A3EB8Q42637732-5FC7CFCA-C502-4220-8DA6-DA77CB849363Q47099325-51A16874-4746-4646-AB5C-20D6BA5FE56DQ47141170-6B5E5C56-261D-41C0-96F7-65C6D72FF62AQ47629716-A893C14A-430D-4C8C-93BD-F7ECAB8CC273Q48179574-264847C1-918D-4A5E-ADCC-0916180ABA1AQ48216923-3EB87799-F8A4-4019-8068-1FD64D528734Q53462999-9D90CAE8-E302-491B-B804-692C4E5F0355Q54307521-466EF058-1044-49FF-B0BE-E0388FC720BD
P2860
Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Azacitidine in 302 patients wi ...... gistry of the AGMT-Study Group
@ast
Azacitidine in 302 patients wi ...... gistry of the AGMT-Study Group
@en
Azacitidine in 302 patients wi ...... gistry of the AGMT-Study Group
@nl
type
label
Azacitidine in 302 patients wi ...... gistry of the AGMT-Study Group
@ast
Azacitidine in 302 patients wi ...... gistry of the AGMT-Study Group
@en
Azacitidine in 302 patients wi ...... gistry of the AGMT-Study Group
@nl
prefLabel
Azacitidine in 302 patients wi ...... gistry of the AGMT-Study Group
@ast
Azacitidine in 302 patients wi ...... gistry of the AGMT-Study Group
@en
Azacitidine in 302 patients wi ...... gistry of the AGMT-Study Group
@nl
P2093
P2860
P921
P1433
P1476
Azacitidine in 302 patients wi ...... gistry of the AGMT-Study Group
@en
P2093
Alois Lang
Christoph Tinchon
Daniela Voskova
Dietmar Geissler
Georg Theiler
Josef Thaler
Konstantin Schlick
Lisa Pleyer
Martin Schreder
Michael Girschikofsky
P2860
P304
P356
10.1007/S00277-014-2126-9
P577
2014-06-21T00:00:00Z